Amplification of the MET gene in NSCLC and mutations leading to MET∆ex14 were first reported in 2005 and 2006, respectively [9, 10], while two seminal works published in 2015 identified MET∆ex14 as a potential therapeutic target in advanced NSCLC [11, 12]. The gene discussed is MET; the disease is non-small cell lung carcinoma.